1. Academic Validation
  2. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader

Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader

  • J Med Chem. 2024 Apr 25;67(8):6880-6892. doi: 10.1021/acs.jmedchem.4c00538.
Md Kabir 1 Lihuai Qin 1 Kaixiu Luo 1 Yan Xiong 1 Rebecca A Sidi 1 Kwang-Su Park 1 Jian Jin 1
Affiliations

Affiliation

  • 1 Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Abstract

Bridged PROTAC is a novel protein complex degrader strategy that exploits the target protein's binding partner to degrade undruggable proteins by inducing proximity to an E3 ubiquitin ligase. In this study, we discovered for the first time that Cereblon (CRBN) can be employed for the bridged PROTAC approach and report the first-in-class CRBN-recruiting and EED-binding polycomb repressive complex 1 (PRC1) degrader, compound 1 (MS181). We show that 1 induces preferential degradation of PRC1 components, BMI1 and RING1B, in an EED-, CRBN-, and ubiquitin-proteosome system (UPS)-dependent manner. Compound 1 also has superior antiproliferative activity in multiple metastatic Cancer cell lines over EED-binding PRC2 degraders and can be efficacious in VHL-defective Cancer cells. Altogether, compound 1 is a valuable chemical biology tool to study the role of PRC1 in Cancer. Importantly, we show that CRBN can be utilized to develop bridged PROTACs, expanding the bridged PROTAC technology for degrading undruggable proteins.

Figures
Products